Tag Archives: BIIB

Best Biotech Stocks To Watch For 2018

This summer, Todd Hagopian and Jason Spatafora told us that traditional Biotech companies are looking at Cannabis-based Biotech stocks as buyout candidates. Since then, the four stocks they recommended are up on average 20%, while the S&P 500 is up less than 2%. We welcome them again to discuss the election and the prospects for the Marijuana stock sector.

Todd Hagopian and....More>>>

Top 10 Biotech Stocks To Buy Right Now

Wednesday was a strong day for the stock market, as the Dow finished up nearly 100 points and the S&P 500 and Nasdaq both posted gains as well. Investors remained generally upbeat about the prospects for the U.S. economy in 2017, and a rise in crude oil prices helped lift the energy sector higher during the market session. Yet comments during a press conference from President-elect Donald Trump....More>>>

Top 10 Biotech Stocks To Invest In Right Now


Flickr

Shares of Foster City, California-based, biotech major, Gilead Sciences, Inc(NASDAQ:GILD) have been on a consistent decline in the last one year or so. After being one of the best performers in the biotech space since 2012, Gilead stock has lost more than 12% in last one year, while theNasdaq Composite (INDX:COMPX) has gained by more than 24% in the same period, resulting in....More>>>

Top 10 Biotech Stocks To Invest In 2018

Today I want to pull back the curtain and explain how I use a little known Federal Drug Administration secret to identify the best biotech stocks that could trigger big profits in months.

One that tells me exactly when drug companies expect to receive approval from the FDA.

This information is an incredibly valuable first step when I begin researching a biotech stock.

Because....More>>>

Top Biotech Stocks To Watch Right Now

Pick a small-cap biotech company, any small-cap biotech company, and you could be picking the winning lottery ticket if its cutting-edge research pans out. And if it doesn’t? Well, then you could end up like StemCells (STEM), which reported lackluster trial data and announced that it would be winding down. Maxim’s Jason Kolbert and Jason McCarthy explain:

Surprising news came....More>>>